Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Biosimilarity of Gan & Lee Insulin Glargine vs Lantus in T1DM
NCT04236895Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin glargine in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Area Under the Serum Insulin Concentration-Time Curve from 0 to 24 Hours, Maximum Serum Insulin Concentration and 2 more. Started Jul 2018; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04236895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04236895.